Introducing the Joint Clinical Assessment (JCA) in the EU: Aiming to Enhance Access to Innovative Therapies but Risking to Duplicate HTA for the Industry
The Joint Clinical Assessment (JCA) process in the European Union marks a significant advancement in the evaluation of innovative therapies
Pricing and Reimbursement France – Securing Early Reimbursement Through the Early Access Programs
France’s Reimbursed Early Access Programs (EAPs) allow for reimbursement of new medicines before traditional reimbursement and even before Marketing Authorization.
HAS Early Access Program: Positive Trends After Two Years
The Haute Autorité de Santé (HAS) has recently shared a two-year summary of its Early Access program. The highlights include:
Pricing and Reimbursement in Germany – Possibility of price increases for legacy products
In an effort to control rising cost Germany introduced both a price freeze preventing price increases on legacy products effective
